Provider of a diagnostic platform for molecular diagnostics and immunoassays. The proprietary DiagCore comprises an Analyzer that runs on consumable DiagCore cartridges. The STAT-Molecular cartridge automates sample homogenization, cell disruption, nucleic acid purification and delivers up to 50-plex target detection employing qPCR. The company operates in Life Sciences > Genomics, Life Sciences > Oncology, Life Sciences > Clinical Genomics. Its business models include Oncology > In-Vitro Diagnostic Tests > Diversified, Genomics > Applied Genomics > Clinical Genomics > Diagnostics > Sequencing-based > Genetic Diagnosis > Immuno-sequencing. Founded in 2010. Headquartered in Spain, Barcelona. The company has raised funding at the Series C stage. Backed by investors including Ysios Capital, Official Credit Institute, Kurma Partners, Idinvest Partners, Boehringer Ingelheim Venture Fund, Caixa Capital Risc, Axis, Next47, Gilde Healthcare, Catalonia Trade & Investment.
STAT Diagnostica
Series CProvider of a diagnostic platform for molecular diagnostics and immunoassays. The proprietary DiagCore comprises an Analyzer that runs on consumable DiagCore cartridges. The STAT-Molecular cartridge automates sample homogenization, cell disruption, nucleic acid purification and delivers up to 50-plex target detection employing qPCR. The company operates in Life Sciences > Genomics, Life Sciences > Oncology, Life…
About
Business model
Oncology > In-Vitro Diagnostic Tests > Diversified,
Genomics > Applied Genomics > Clinical Genomics > Diagnostics > Sequencing-based > Genetic Diagnosis > Immuno-sequencing
Institutional investors
Latest coverage
📰 Browse funding news — rounds, valuations, and market moves for founders.
Backed by funds in our directory
🗂️ See who's investing in Life Sciences — full fund directory with check size and geography.